GSK and Merck & Co have both reported new clinical data with the PD-1 checkpoint inhibitors, seeking an edge in the first-line treatment of advanced endometrial cancer. Results of GSK’s RUBY trial of ...
He comes with cash to burn, a fleet of airplanes, and a keen eye for the ladies — to say nothing of a relentless brain that challenges Nobel Prize–winning scientists across the country — and for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback